Objective: A pilot study was conducted to longitudinally quantify effect of onabotulinum toxin A (BoNT-A) on passive muscle properties in children with cerebral palsy using ultrasound shear wave elastography. Design: This was a prospective longitudinal cohort study. Results: Between 1 and 3 mos post-BoNT-A, a significant improvement in the shear modulus of the lateral gastrocnemius was found at 10-degrees plantar flexion (PF) (−7.57 [−10.98, −5.07], P = 0.02) and 0-degrees PF (−14.74 [−18.21, −9.38], P = 0.03). There was a notable, but nonsignificant, difference in shear modulus at 20-degrees PF, 10-degrees PF, and 0-degrees PF between pre-BoNT-A and 1 mo post-BoNT-A. Pre-BoNT-A shear modulus was not significantly different from 3 mos post-BoNT-A at all foot positions. No significant differences in ankle passive range of motion or spasticity were found. Conclusion: Despite no significant change in ankle range of motion or spasticity, shear wave elastography was able to detect a difference in lateral gastrocnemius passive muscle properties in children with cerebral palsy after BoNT-A injections. The difference in passive muscle properties resolved by 3 mos post-BoNT-A.
I
n individuals with cerebral palsy (CP), spasticity is a common target for therapeutic intervention. Spasticity, defined in 1979, is a "motor disorder characterized by a velocitydependent increase in tonic stretch reflexes ('muscle tone') with exaggerated tendon jerks, resulting from hyperexcitability of the stretch reflex."
1 Spasticity has a short-latency, phasic component (hyperreflexia) and a late, sustained activity component (hypertonia). 2, 3 The mechanism in which spasticity results in abnormal muscle stiffness is not clear but likely contributes to increased active stiffness through the sustained hypertonia, leading to maladaptation of muscle architecture (i.e., sarcomere muscle fascicle lengths 4 and increased collagen content of the extracellular matrix of the muscle 5 ) affecting the passive muscle stiffness. Recently, using a noninvasive ultrasound technology, ultrasound shear wave elastography (SWE), it has been shown that passive muscle stiffness is significantly greater in children with CP as compared with age-and sexmatched typically developing children. 6 This increased passive muscle stiffness in children with CP is thought to contribute to the development of muscle contractures and boney deformity.
Intramuscular botulinum toxin injections are commonly used to facilitate focal and temporary spasticity reduction in children with CP. Botulinum toxin injections are considered effective for spasticity reduction in children with CP and, when used in combination with physical and occupational therapy, may improve ambulation and hand function. 7 Botulinum toxin injections have also been shown to improve passive range of motion (ROM). 8 However, even with repeated injections, this improvement may only be temporary. 9 Optimizing passive muscle stiffness and preventing contracture development is important as improved passive ROM has been associated with improved physical functioning. 10 Thus, furthering our understanding of the effect of botulinum toxin on passive muscle stiffness through direct measurement of passive muscle stiffness in children with CP is needed. This study has not been possible until recently, as previous methods for evaluation of passive muscle stiffness have been limited by inability to isolate individual muscles. Clinical measures of spasticity, including the Modified Tardieu and Ashworth scales, have subjectivity in the interpretation of the limb movement and limited reliability in repeated measures, particularly when used in young children with CP. 11, 12 Other tests including dynamometry, Ramp and Hold Test, and the Pendulum test can be challenging to perform and do not isolate passive muscle stiffness from joint or tendon stiffness. In contradistinction to these measures and tests, SWE is an ultrasound technique that can be used to quantify passive muscle stiffness in children and adults. 6, 13, 14 Thus, this study is a longitudinal pilot study involving children with spastic CP who were planning to undergo onabotulinum toxin A (henceforth, BoNT-A will refer to onabotulinum toxin A) injections at the authors' institution. Clinically, BoNT-A has a plateau of its peak effect on spasticity reduction by approximately 1 to 2 mos postinjection and loss of clinical effectiveness by 3 mos postinjection. 15 However, it is not clear if spasticity reduction coincides to changes in passive muscle properties. Therefore, this pilot study aimed to use SWE to quantify the effect and the duration of effect of BoNT-A on passive muscle stiffness in children with CP. This is a step toward creating a clinically feasible tool for monitoring effect and duration of effect of BoNT-A on passive muscle stiffness to provide evidence-based and individualized treatment.
METHODS

Participants
Ten children aged 2 to 12 yrs with spastic CP who were undergoing BoNT-A injections to the gastrocnemius muscle for clinical reasons were recruited from Mayo Clinic's Cerebral Palsy Clinic. Children were excluded if they had (1) any surgery to the tibia or fibula, gastrocnemius/soleus, or Achilles tendon, (2) any other orthopedic surgery to the lower limb in the previous 6 mos, (3) any phenol injection to the limb of interest in the previous 6 mos, (4) botulinum neurotoxin injection to the lower limb of interest in the previous 3 mos, (5) planned active titration of systemic antispasticity medications during the study period, (6) serial casting of the lower limb of interest in the previous 6 mos, or (7) inability to tolerate positioning for the study. Children could be undergoing BoNT-A injections to other muscles during the same session as the gastrocnemius injection session. Mayo Clinic Institutional Review Board approval was obtained before initiating the study. Written informed consent was obtained from a parent or guardian of each child, with written assent obtained from children if older than 7 yrs and cognitively able to provide assent.
Study Methods
This study consisted of a total of three study visits for each child. These visits were performed at time points of up to 1 mo before BoNT-A injections, 1 mo after BoNT-A injections, and 3 mos after BoNT-A injections. The follow-up time points corresponded with clinically expected timing of plateauing of the peak effect and wearing off of effect. 15 Demographic information, physical examination, and SWE measurements were obtained at each visit as outlined below. With regard to the BoNT-A injections, BoNT-A was dosed and injected per the typical prescribing and injecting technique of the treating physician, representing the usual clinical practice of the physicians. At the authors' institution, BoNT-A injection amounts are divided equally between the medial and lateral heads of the gastrocnemius muscle. Injection technique was per the injecting physician. For all children in this study, anatomic identification (area of greatest muscle bulk on the posterior calf ) and electrical stimulation were used for optimizing placement of injections.
For each child, demographic information collected included date of birth, weight, height, sex, medical and surgical history, medications, and previous botulinum toxin or phenol injections. Physical examination measurements collected were spasticity using the Modified Ashworth Scale (MAS), ankle passive ROM, Gross Motor Function Classification Scale (GMFCS) level, and type of CP. MAS testing for the ankle was performed with the child either seated or supine, depending on the child's ability and preference. Whereas the reliability of the MAS for measuring spasticity has come into question, the Modified Tardieu Scale has been shown to have similar interrater and intrarater reliability as the MAS, although in a subsequent version by Gracies et al., training does appear to improve reliability of the Tardieu Scale measurements. 12, 16, 17 Maximum passive joint ROM of the ankle for foot dorsiflexion (DF) and plantar flexion (PF) was performed using a goniometer with the child in supine position. When supine, the child's hip was positioned at 0-degrees extension and knee was placed in full extension (0-degrees flexion). If the child did not have the ROM at the hip or knee to accommodate this positioning, the nearest position that the child could comfortably tolerate was used. Maximum passive ankle ROM was achieved when either the child demonstrated discomfort, either verbally or through other indications or a solid end point was reached with stretch.
After the physical exam measurements, measurements of lateral gastrocnemius stiffness of the most affected leg were performed using SWE. The most affected leg was the side, with greater gastrocnemius spasticity as determined by MAS score and/or lesser ankle DF passive ROM. An Aixplorer ultrasonic scanner (SuperSonic Imagine, Aix-en-Provence, France) with a linear array transducer (SL15-4; SuperSonic Imagine, Aix-en-Provence, France) was used with musculoskeletal preset. The physics and mathematical approach for these measurements are described elsewhere. [18] [19] [20] Briefly, the ultrasound probe generates transient shear waves in muscle by transmitting ultrasound push beams. 19 The same probe then detects the shear waves travelling along the muscle fiber, the speed of which can be used to calculate the Young modulus. 18, 21 Young modulus is the output of the Aixplorer. SWE measurements were obtained as previously described. 6, 13 Briefly, each child was assisted into a prone position with feet over the edge of the examination table. With a tape measure, circumferential measurements of the limb of interest were obtained, and the area of greatest muscle bulk was marked on the skin. The ultrasound transducer was positioned on the lateral gastrocnemius muscle over the area of greatest muscle bulk. The transducer was aligned with the direction of the muscle fiber. The distance from the fibular head to the proximal end of the ultrasound probe was measured and recorded to maintain positioning of the ultrasound transducer for the repeated measures. B-mode imaging was used to confirm positioning and alignment of the transducer. Appropriate transducer alignment was achieved when several fascicles of the lateral gastrocnemius could be traced (Fig. 1) . The transducer was held in place with minimal pressure on skin by one of the examiners. Surface electromyography (U-Control; Thought Technology Ltd, Québec, Canada) was used to ensure muscle relaxation. The U-Control was set at lowest scale range (X1, upper threshold 3.0) for detecting muscle activation. Electrodes were placed over the posterior calf near the area of the SWE measurement. A goniometer was used to ensure placement of the foot in 20-degrees PF, 10-degrees PF, and 0-degrees PF. The goniometer was aligned with the shaft of the tibia or fibula and the calcaneus. The examiner then applied pressure along the plantar surface of the foot, using calcaneal movement as the DF measurement and observing for inadvertent foot rotation or inversion/eversion. When correct foot position and sufficient muscle relaxation were present, SWE measurement was performed. Measures were obtained at three positions and then repeated twice. The three measures for each foot position were averaged to generate a single value for further analysis.
The output for each SWE measurement is a two-dimensional elastogram (Fig. 1) . On this elastogram, a region of interest over the lateral gastrocnemius muscle was selected such that muscle fascial borders, tendon, and blood vessels were excluded. As previously described, 6, 13, 14 an open-source imaging plug-in for the DICOM reader (OsiriX Imaging Software, Geneva, Switzerland) was used to measure the mean Young modulus for the circular region of interest (mean diameter, 4.8-5.0 mm) within the SWE elastogram. The mathematical conversion from the shear wave speed to the Young and shear modulus assumes that the material is purely elastic, locally homogeneous, and isotropic. These assumptions do not apply to muscle. However, strong correlations have been found between the muscle shear modulus measurement from SWE and Young modulus measurements from traditional material testing. 21 These correlations indicate that shear modulus measurements from SWE may be used to represent the true Young modulus of the muscle. Therefore, Young modulus was converted to shear modulus by the formula E = 3 μ, where E is the Young modulus and μ is the shear modulus. As shear modulus is the accepted measurement for reporting on anisotropic tissues such as muscle, the shear modulus is reported as the SWE measurement. 6, 13, 20, 21 
Statistical Analysis
Differences between lateral gastrocnemius shear modulus before, 1 mo after BoNT-A, and 3 mos after BoNT-A at each foot position for the most affected leg in children with CP were of primary interest. Categorical variables (i.e., sex, GMFCS, MAS, and CP type) were summarized using frequency and percentages. Continuous variables (i.e., age, body mass index, calf circumference, maximal ankle DF, and shear modulus) were summarized using median, interquartile range (Q1, Q3) and range. Paired t tests were used to compare differences over time with respect to shear modulus, MAS, calf circumference, and ankle DF passive ROM. Spearman rank correlations were used to explore the relationship between pairs of continuous variables (shear modulus and BoNT-A dose, shear modulus, and ankle DF passive ROM). Because of the limited sample size, Kruskal-Wallis tests were used when comparing across three groups (GMFCS, CP type, and history of any previous botulinum toxin injections). The level for significance for any P value was set at less than 0.05. All analyses were conducted using SAS for Unix (version 9; SAS Institute Inc).
RESULTS
A total of 10 children with CP were recruited for the study. One child was excluded after testing as he was unable to achieve muscle relaxation, despite multiple attempts at alternative positioning to facilitate comfort and relaxation. Therefore, nine children were used for analysis. Demographics, physical examination characteristics, and amount of BoNT-A injected are described in Table 1 . The children ranged in age from 2 to 9 yrs. All children were ambulatory (GMFCS I-III). Just over half of the children were boys (5 [55.6%]), had bilateral CP (5 [55.6%]), and had a history of BoNT-A injections to the gastrocnemius muscle (5 [55.6%]). Of those who had a previous BoNT-A injection to the gastrocnemius muscle, 6 mos was the shortest period from previous injection. Some children with CP had a maximal ankle DF of less than 0 degrees during their initial goniometric testing (which was always performed before SWE). All these children were able to achieve 0-degrees DF during SWE testing.
A significant change was found in shear modulus of the lateral gastrocnemius muscle at 10-degrees PF between 1 and 3 mos post-BoNT-A and at 0-degrees PF between 1 and 3 mos post-BoNT-A (Table 2, Fig. 2 ). There was a notable, but nonsignificant, difference in shear modulus of the lateral gastrocnemius muscle at 20-degrees PF, 10-degrees PF, 0-degrees PF between pre-BoNT-A and 1 mo post-BoNT-A (Table 2 , Fig. 2 ). Pre-BoNT-A shear modulus of the lateral gastrocnemius muscle was not significantly different than 3 mos postBoNT-A at all foot positions.
In addition, three (33.3%) of the children had improved MAS scores at 1 mo post-BoNT-A, with two children having a one-point improvement and one child having a two-point improvement. None had worsening of the MAS at 1 mo postBoNT-A. Two (22.2%) children sustained this improvement at 3 mos post-BoNT-A. However, the overall changes in MAS were not statistically significant at the time points evaluated. With respect to maximal ankle DF, five (55.6%) children had improvement at 1 mo post-BoNT-A, with 4 (44.4%) children showing a reduction in maximal ankle DF. Two (22.2%) children maintained the improvement in maximal ankle DF at 3 mos post-BoNT-A and six (66.7%) children showed a reduction in maximal ankle DF from the initial visit at 3 mos. Despite these changes, maximal ankle DF did not significantly change across time points. Calf circumference was also not statistically different across the time points, with all but one child having a calf circumference within 1 cm of the initial visit measurement at 1 and 3 mos post-BoNT-A (summarized in Table 1 ).
DISCUSSION
BoNT-A (not approved by the Food and Drug Administration for the treatment of spasticity in children) seems to provide temporary improvement in passive muscle stiffness of the lateral gastrocnemius. Improvements in passive muscle stiffness were greatest at 1 mo post-BoNT-A (at anticipated peak of effectiveness), with the largest difference at the maximum stretch that was measured (0-degrees PF). These improvements were statistically significant between 1 mo post-BoNT-A and 3 mos post-BoNT-A at 10-degrees PF and 0-degrees PF. Notable changes in passive muscle stiffness from pre-BoNT-A and 1 mo post-BoNT-A were also found at all foot positions, but these did not reach statistical significance, likely contributing factors include the number of children in the authors' pilot study and the large standard deviations in SWE measurements of the lateral gastrocnemius muscle pre-BoNT-A. Interestingly, whereas passive muscle stiffness of the lateral gastrocnemius did temporarily improve with BoNT-A injections, in this study, a significant change in ankle passive ROM was not found. Thus, the improvement in passive stiffness may make it easier to stretch the gastrocnemius within the passive ROM that the child had before the injections but does not result in greater passive ROM. This has some correlation to earlier work by Alhusaini et al., 22 who looked at the effect on BoNT-A on gastrocnemius hysteresis. Although the authors did not find a significant difference in hysteresis, the hysteresis curve was shifted downward following BoNT-A injections, suggesting less torque (implying muscles were less stiff ) to perform the passive ROM after BoNT-A. 22 The children with CP in that study were all high-level ambulators (GMFCS I and II) and had greater ankle passive ROM than the children in this study, which suggests the children in the previous study had less passive stiffness than the children in this study and/or the children in this study may have developed fixed muscle contracture. Fixed muscle contracture occurs despite use of BoNT-A, as shown in a retrospective study evaluating long-term effects of BoNT-A. 9 One potential reason for a lack of joint contracture prevention with BoNT-A is a chronic maladaptation of sarcomeres in the muscle of children with CP. Specifically, in vivo studies have shown that muscle fibers of children with CP have fewer sarcomeres in series, with these sarcomeres being longer. 5, 23 Thus, there may be less ability of the muscle to adapt or respond to passive stretching, even when spasticity is reduced. In addition, there may be fewer satellite cells in muscles of children with CP, thus reducing the regenerative ability of the muscles fibers (i.e., ability to generate more sarcomeres in series). 24 These studies suggest that by time a child with CP develops maladaptive changes in joint passive ROM or increasing difficulties with physical functioning, the muscle may have limited capability to adapt, even with spasticity reducing interventions, due to intrinsic changes in the muscle.
Although BoNT-A is intended to reduce spasticity, in this study, a significant reduction in spasticity was not found in the group of children studied. A lack of significant spasticity reduction may be multifactorial, including the numbers of children in this pilot study, resistance to BoNT-A for those previously injected, dose used in the gastrocnemius, possibility of inadvertent soleus injection, and the lack of sensitivity of the MAS. [25] [26] [27] In future studies, the authors would like to investigate the correlation of the Dynamic Muscle Length portion of the Modified Tardieu Scale to SWE measurements of passive muscle stiffness changes with interventions to reduce spasticity. 28 The rationale for using the Modified Tardieu Scale is that it has two measurements of particular interest. 28 The first is the measurement of the joint angle at which the spastic catch is felt (designated as R1). The second is the measurement of the full passive ROM (designated as R2). The difference between R2 and R1 is termed the dynamic component. Given this study's findings of a reduction in passive muscle stiffness of the lateral gastrocnemius at 1 mo post-BoNT-A, without a significant change in joint passive ROM, it is anticipated that BoNT-A has its greatest effect on reducing the dynamic component (i.e., reduces the difference between R2 and R1). This reduction in the dynamic component may facilitate more functional ROM, by delaying the range in which the spastic catch is generated.
LIMITATIONS
There are a few limitations to this study. First, this is a pilot study. The authors identified statistical improvement of passive muscle properties with BoNT-A and evaluated a few associations but, because of sample size, were not able to explore additional correlations or draw more definitive conclusions on the associated factors investigated. With optimization of this study's protocol, future studies with a larger number of participants can be done to investigate other factors, such as dose of BoNT-A, effect of repeated BoNT-A injections on passive muscle stiffness, and correlations with clinical spasticity measures including the Dynamic Muscle Length component of the Modified Tardieu Scale. The authors would also like to investigate duration of effect of differing BoNTs on passive muscle stiffness and of other spasticity reducing techniques (selective dorsal rhizotomy, intrathecal baclofen pump, and oral medications) on passive muscle stiffness. Finally, the authors plan to investigate the relationship of passive gastrocnemius muscle stiffness and spasticity reducing interventions with ankle kinematics, kinetics, and temporal distance factors (i.e., step length and stride length) during walking in future studies. Another limitation is a lack of children of more severe impairments (GMFCS levels IV and V). It was difficult recruiting children with greater functional impairments as the parents felt their child would not tolerate positioning, would not be able to cooperate with testing (primarily due to cognition), or could not come back for the testing because of difficulty in transporting their child. The one child recruited of GMFCS IV had great difficulty with positioning and relaxation. However, a short time after completion of the study, he was diagnosed with autism, which may have contributed to his difficulties with participation. In a previous study, it was noted that, overall, children with CP had greater difficulty with muscle relaxation (as monitored with surface electromyography) than did typically developing children requiring longer study visits and occasional breaks during testing. 6 The authors did not time study visits to see if this changed over the course of participation in the study (i.e., either due to BoNT-A facilitating relaxation or due to having an understanding of the study procedures). But this could be done in future studies. To maintain the clinical applicability and clinical translation of this study, ankle passive ROM was chosen to be measured using a goniometer. The goniometer method has a variability of approximately 5 to 14 degrees in children with CP. 29, 30 This may be why some children with CP who had maximal ankle DF of less than 0 degrees during their initial goniometric testing were able to achieve 0-degrees DF after this initial testing. This difference in initial passive ROM was the result of a response to initial stretch for goniometric measurement (which was always performed before SWE), inherent variability in goniometric measurements, or both. This range of variability in this measurement may have also contributed to the lack of significant difference in the passive ROM outcomes. In future studies, adding a measure of torque required for performing passive ROM (via biomechanics laboratory) and goniometer testing would provide additional information in this area.
Lastly, the dosing of BoNT-A was not controlled, but rather done based on clinical judgment of the treating pediatric rehabilitation physician. Thus, many children received BoNT-A injections to multiple muscles, as was clinically indicated. For many children, this limited the dose of BoNT-A, which could be injected to the gastrocnemius muscle, with the median dose in this study being 3.3 units/kg. This dose is on the lower end of the recommended dosing for a large muscle in the leg but is consistent with clinical practice in which more than one muscle is injected. 27 
CONCLUSIONS
In this pilot study, BoNT-A injections provide temporary, but statistically significant, improvement in passive gastrocnemius muscle stiffness. There was no statistically significant improvement in joint passive ROM or spasticity, possibly because of the limitations of the study; thus, the clinical significance of the change in passive muscle stiffness remains unclear. Continued work to advance the understanding of the mechanisms underlying the development of the abnormal passive muscle stiffness, along with identifying clinically meaningful changes in passive muscle stiffness, is critical for targeting prevention of the development of abnormal passive muscle stiffness and identifying interventions to provide long-term improvement.
